Users' Attitudes, Perception, and Concerns in the Era of Whole Genome Sequencing

Emiliano De Cristofaro

PARC (a Xerox Company) 3333 Coyote Hill Road, Palo Alto, CA 94304

Abstract

Advances in Whole Genome Sequencing (WGS) will soon allow a large number of individuals worldwide to have access to their sequenced genome, yielding momentous medical and societal consequences. However, this process also comes with the risk of amplifying a number of ethical and privacy concerns, that have been analyzed both by the research and the policy communities. In this paper, we turn to non-expert users and begin to assess their perception of privacy and ethical issues with WGS, their attitude toward different WGS programs, as well as their general perception of genetic tests. We report on a series of semi-structured interviews, involving 16 participants, and analyze the results both quantitatively and qualitatively. Our preliminary studies yield some interesting findings and highlight the need for more ethnographic studies in the field.

1 Introduction

In the past half a century, DNA sequencing—the process of determining the precise order of nucleotides within a DNA molecule—has constituted one of the most active and fast-paced research frontiers. The first complete human genome was sequenced in 2007 as part of the 13-year Human Genome Project [30, 49]. Thereafter, we have witnessed an exciting race toward faster, cheaper, and more accurate Whole Genome Sequencing (WGS) technologies. Costs have quickly plunged from Human Genome Project's \$1B [26] to \$250K in 2008 [41] and to less than \$5K in 2010 [11, 12]. In 2012, it was reported that the \$1,000 mark would soon be crossed [23, 36]. The landscape of companies and technologies in WGS is fast-evolving, nonetheless, it is not far-fetched to predict that, in 5-10 years, most individuals in developed countries will have access to their sequenced genome.

The emergence of affordable WGS technologies rep-

resents, undoubtedly, an exceptional breakthrough, due to the related medical and societal implications. Experts predict that advances in WGS will unlock the full potential of *personalized medicine* [18]—the practice of tailoring pre-symptomatic examinations, diagnosis, and treatment to patients' genetic features. A number of companies (e.g., 23andMe.com and Knome) already provide customers with detailed reports on predisposition to diseases and conditions. A few drugs (e.g., for cancer, HIV, or thrombosis treatment) are paired with genetic tests needed to assess either the correct dosage or their expected effectiveness [1, 7, 38, 39].

Arguably, the availability of patient's wholly sequenced genome enables clinicians, doctors, and testing facilities to run a number of complex genetic tests in a matter of seconds, using specialized computational algorithms (as opposed to more expensive and slower laboratory tests). On the other hand, however, WGS also comes at the risk of amplifying important security, privacy, and ethical concerns, overviewed in Section 2.2, that stem from the unparalleled sensitivity of DNA data [10].

The emergence of personal genomic tests as well as the anticipated availability of affordable Whole Genome Sequencing (WGS) motivate the need for better understanding associated perceptions and concerns of involved users. Computational genomic tests that involve end-users should be usable by, and meaningful to, regular non-tech-savvy individuals. This translates into non-trivial questions, such as: how much understanding should be expected from a user running a test? Do privacy perceptions and concerns experienced by patients correspond to what the scientific community would expect? How can we identify effective mechanisms to communicate potential privacy risks associated with genomic information and its disclosure?

A few studies (see Section 3) have analyzed individuals' response to learning the results of some genetic tests and potential discrimination concerns associated with ge-

nomics. However, to the best of our knowledge, no study, thus far, has focused on scenarios enabled by *WGS*.

In this paper, we start addressing this gap and present the results of a series of (IRB-approved) semi-structured interviews, involving 16 participants, aiming to assess the perception of privacy and ethical issues with WGS, the attitude toward different WGS programs, as well as the overall perception of genetic tests. Results are analyzed both quantitatively and qualitatively, yielding several interesting findings related to the issues of control, trust, and discrimination, and highlighting the need for more ethnographic studies in this field.

Paper Organization. The rest of the paper is organized as follows: next section presents background information about genomics and privacy/ethical concerns, then, Section 3 reviews related work. In Section 4, we present our study design and participants' demographics, while Section 5 analyzes study results, both quantitatively and qualitatively. The paper concludes with Section 6.

2 Background

2.1 Genomics

Personalized Medicine. Personalized Medicine refers to the practice of tailoring pre-symptomatic examinations, diagnosis, and treatment to individuals' genetic features. In this field, 23andMe.com is among the best-known commercial companies: they provide customers with a low-cost (about \$100) report assessing their genetic risk toward a number of diseases and conditions (by testing for almost a million specific Single-Nucleotide Polymorphisms (SNPs) [37, 45]).

Genomic tests today are increasingly and more effectively used in healthcare. For instance, testing for the thiopurine S-methyltransferase (*tpmt*) gene is required prior to prescribing some drugs used for treating childhood leukemia [1]. Similarly, doctors prescribing Zelboraf (Roche's treatment for skin cancer) need to test the patient for the BRAFV 600E mutation. Other analogous examples include testing for mutations in the Philadelphia chromosome (in Acute Lymphoblastic Leukemia patients) or in BRCA1/BRCA2 genes (in breast and ovarian cancer patients).

Experts estimate that about a third of the 900 cancer drugs currently in clinical trials could soon come to market with a DNA or other molecular test attached [7]. Although most predominant, cancer treatment is only one of the application fields of personalized medicine. For instance, for some cardiac patients, recovery from a common heart procedure can be complicated by a single gene responsible for drug processing, and selection of blood thinner drugs should depend on whether or not patient

holds such a gene mutation [51].

Recent years have also witnessed important progress in *pharmacogenomics*, i.e., the study of the impact of genetic variation on the response to medications. For instance, researchers have discovered genes encoding Cytochrome P450 enzymes, which metabolize neuroleptic medications to improve drug response and reduce side-effects [9], and also genes involved in the action and metabolism of warfarin (coumadin) – a medication used as an anticoagulant [38].

Genetic Tests. The availability of whole human genomes will also facilitate a number of genetic tests that today are performed in vitro, by reducing costs and time. For instance, ancestry and genealogical tests allow individuals to trace their lineage by analyzing their genomic information (the scope of such tests being often quite heterogeneous). Ancestry testing is increasingly popular, e.g., to map one's own genetic heritage and/or find known ancestry. Several commercial entities (e.g., 23andMe.com and Ancestry.com) provide customers with reports on their genetic ancestry. They maintain a collection of sample genomes from individuals belonging to different ethnic groups, and compare them against their customers' genomic information to understand how they relate to known ethnic groups.

Genetic compatibility tests are used to let (potential or actual) partners assess the possibility of transmitting to their children a genetic disease with Mendelian inheritance [35]. For instance, Beta-Thalassemia minor causes red cells to be smaller than average, due to a mutation in the hbb gene. It is called minor when the mutation occurs only in one chromosome, while the major variant—that occurs when both chromosomes carry the mutation—is likely to result in premature death. Therefore, if both partners carry the minor form, there is a non-negligible chance that their child will carry the major variant.

2.2 Privacy and Ethical Concerns in WGS

While advances in genomics and sequencing technologies potentially unlock a wide range of inherent and anticipated benefits, they also come at the risk of amplifying security, privacy, and ethical concerns.

The human genome not only uniquely and irrevocably identifies its owner, but also contains information about ethnic heritage, predisposition to numerous diseases and conditions, including mental disorders [13, 8, 15]. Recent studies suggest a strong correlation between political preferences and voters' genetic makeup [3]. Furthermore, due to its hereditary nature, disclosing one's human genome also implies, to a certain extent, disclosing the genomes of close relatives.

Traditional approaches to privacy, such as deidentification or aggregation [31], might not be effective when applied to genomic information. [21] demonstrates the feasibility of re-identifying DNA donors from a public research database using information from popular genealogy websites. (Additional results on DNA re-identification include [32, 33, 34, 25, 48].)

As the human genome contains detailed information about susceptibility to somatic and mental conditions, ethnicity, etc., its disclosure is often associated to fears of *eugenism*, i.e., genetic discrimination, thus potentially affecting social dynamics as well as hiring and healthcare practices. (We refer to [16] for a survey of self-reported genetic discrimination.)

These concerns creates the need for informed consent to guard against surreptitious DNA testing by requiring authorities and companies to obtain written permission from citizens before collecting, analyzing, storing or sharing their genetic information (e.g., preventing people from collecting hair or saliva samples and maliciously sequencing the victims' genome). However, on the other hand, such privacy-restrictive measures are often regarded as a potential obstacle to genomic research. Scientists typically sequence DNA from thousands of people to discover genes associated with particular diseases, thus, the informed consent restriction would mean that large genomic datasets could not be re-used to study a different disease - researchers would either need to destroy the data after each study, or track down thousands of former subjects for new authorizations [43].

3 Related Work

The emergence of personal genomic tests and affordable Whole Genome Sequencing (WGS) motivate the need for better understanding related perception and concerns of involved users. However, much is left to be studied, since, to the best of our knowledge, *very limited work has focused on studying the human factor in Whole Genome Sequencing*.

Francke et al. of 23andMe.com [14] interviewed 63 23andMe.com customers that tested for BRCA mutations. (BRCA gene mutations convey a high risk for breast and ovarian cancer). They analyzed customers' response among 32 mutation carriers (16 women, 16 men) and 31 non-carriers and concluded that direct access to BRCA mutation tests provided benefits to participants. None of the 25 users that had unexpectedly found out to carry the mutation reported extreme anxiety, and 4 experienced moderate, transitory anxiety, similar to the findings by Hamilton et al. [24]. Additional studies analyzing patients' response to genetic tests for disease predisposition include [44] (colon cancer), [19] (Alzheimer's disease), [4, 6] (breast cancer). Also, Andrews [2] analyzed the concept of "survivor's guilt" experienced by individuals learning not to carry a harmful mutation, while a family member does.

Brothers et al. [5] found out that, when asked about an opt-out consent process, over 90 percent of participants agreed or strongly agreed that "DNA biobank research is fine as long as people can choose not to have their DNA included." Some studies highlighted how privacy concerns are often an important obstacle to participation in large cohort studies [50]. Although 60 percent of people surveyed said they would participate in a study that involved storing data in biorepositories, 91 percent of those potential research participants would be concerned about privacy [27]. Another study showed that, while participants trusted clinicians and researchers, they were concerned that results of genetic tests could end up in the wrong hands and be used against them [17].

Lapham et al. [29] were among the first, in 1996, to analyze consumers' perspectives as to genetic discrimination and reported that people cited fear of losing insurance as a major reason to avoid genetic testing. However, discrimination by insurance companies was not a widespread reality in the 90s, as few of these cases had been filed and even fewer had been won [22]. Many states have passed laws to protect medical (and also genetic) information, such as the Health Insurance Portability and Accountability Act (HIPAA), which provides a general framework for sharing and protecting Protected Health Information. In the U.S., there also exists legislation specific against genetic discrimination the Genetic Information Nondiscrimination Act (GINA) - which prohibits discrimination on the basis of genetic information with respect to health insurance and employment [47]. However, neither GINA or HIPAA placed any limits on health insurance rate setting.

Also, a large body of work analyzed the issue of labor discrimination in relationship to disease predisposition, mostly from the legal standpoint. We refer to the work by Guttmacher et al. [20] for details, along with a review of well-known rulings.

Ruiz et al. [42] compared the attitude of 279 patients from the United States and Spain who had volunteered to donate a sample for genomic research, and showed that 48% of participants would like to be informed about all individual results from future genomic studies using their donated tissue, especially those from the U.S. (71.4%) and those believing that genetic information poses special risks (69.7%).

Trinidad et al. [46] explored the attitude of research participants and possible future participants regarding Genome-Wide Association Studies (GWAS): they found out that participants expressed a variety of opinions about the acceptability of wide sharing of genetic and phenotypic information for research purposes through large, publicly accessible data repositories. Most believed that making de-identified study data available to

Age	N	%
18-24	2	12.5%
25-34	7	43.7%
35-44	3	18.7%
45-54	1	6.2%
55-64	1	6.2%
65-75	2	12.5%

Degree	N	%	Yearly Income	N	%
College	4	25%	Less than \$50K	3	18.7%
Master	8	50%	\$50K-\$75K	3	18.7%
PhD	4	25%	More than \$75K	10	62.5%

Westin Index	N	%
Unconcerned	4	25.0%
Pragmatist	7	43.7%
Fundamentalist	5	31.2%

Table 1: Participants breakdown by age, education, (personal) yearly income, and Westin's Privacy Index [28].

the research community was a social good to be pursued. Privacy and confidentiality concerns were common, although not necessarily precluding participation. Also, many participants voiced reservations about sharing data with for-profit organizations.

Finally, a recent report from the Presidential Commission for the Study of Bioethical Issues [40] analyzed advances of Whole Genome Sequencing (WGS), and focused on potential privacy and ethical threats. The report listed 12 recommendations and provided a high-level effort to identify and promote policies and practices that ensure scientific research, healthcare delivery, and technological innovation are conducted in a socially and ethically responsible manner.

Thus, we conclude that, while prior work has thoroughly analyzed response to learning genetic test results as well as discrimination concerns associated with genomics, there is the need for better analyzing the human factor in WGS.

4 Interview Methodology

Our study consisted of a series of semi-structured interviews with 16 participants (8 female, 8 male). It was reviewed and approved by PARC's Institutional Review Board. Participants were recruited using social networks and internal mailing lists of a university and a company, announcing a study on the "knowledge and perception of DNA testing."

4.1 Participants

The 16 participants ranged in ages from 18 to 74, with 43% of them being between 25 and 34 years old. All were college educated, with 75% of them possessing a post-graduate degree. We deliberately decided to recruit users with higher education and more participants in the 25-34 age range as they constitute the representative population for personal genomic tests. We also collected information about their personal yearly income, and assessed their Westin's Privacy Index [28]. Demographics breakdown is reflected in Table 1.

Users volunteered to participate in the study, i.e., they received no monetary incentive. We decided to do so in order to recruit motivated users who were likely to possess some understanding of genetics.

4.2 Experiments

Interviews lasted approximately 30 minutes (on average) and consisted of three parts: (1) first, we asked participants to provide 1-2 examples of genetic tests and describe their familiarity with genetics; (2) we interviewed participants while guiding them through a set of slides² depicting a few hypothetical scenarios (this constitutes the core of our study, see details below); (3) in order to collect demographic information and assess their Westin Privacy Index [28], participants were asked to fill out a short survey.

We aimed to conduct the four experiments presented in Table 2 below.

Exp. A	Assessing the perception of today's
	genetic tests
Exp. B	Comparing the attitude toward different
	WGS programs
Exp. C	Assessing the perception of potential
	privacy/ethical issues with WGS
Exp. D	Comparing the response to medical,
	genomic, and personal information loss

Table 2: Overview of study experiments and goals.

4.2.1 Experiment A: Perception of genetic tests

Participants were shown the following six examples of genetic tests. Note that the order in which the test scenarios were actually presented was randomized across multiple participants.

(A.1) Disease Predisposition (Doctor.) Scott goes to see his primary care doctor. The doctor asks Scott to run some genetic tests to assess (genetic) predisposition to certain diseases. After collecting a DNA sample (e.g., saliva), the clinic runs some tests on Scott's DNA, and the doctor tells Scott that he is predisposed to type-2 diabetes, but not to Alzheimer's.

¹The Westin's Privacy Index [28] classifies users among privacy fundamentalists, pragmatists, and unconcerned, according to their responses to a simple three-question survey.

²Material used in our interviews is available upon request. Reviewers can obtain it, anonymously, via the PC chairs.

(A.2) Genetic Compatibility. Emma and Scott are planning to have kids. Emma has Beta-Thalassemia Minor, a genetic disorder inherited by only one of her parents, which causes her red cells to be smaller than usual but poses no critical health threat to her. However, if Scott also has the same disorder, there is a chance that their kids will have the Major form, which may cause premature death. Therefore, Scott is advised to take a genetic test to make sure that he doesn't have the disorder.

(A.3) Genetic Ethnicity. Scott is a customer of a genealogy company, such as, Ancestry.com, which analyzes genetic ethnicity and reveals where one's ancestors were form. Scott needs to send a DNA sample (e.g., saliva) to the company, which, after running some tests, tells Scott that his ethnic origins are 39% Scandinavian, 17% Central European, etc.

(A.4) Disease Predisposition (Company.) Scott is a customer of a personal genomics company, such as, 23andMe.com, which provides its customers with a detailed report on their genetic chances of getting a number of diseases, like type-2 diabetes, Alzheimer's, schizophrenia, etc. For each disease, the report includes a risk percentage, the known average risk percentage, and a confidence score. Scott needs to send a DNA sample (e.g., saliva) to the company, which, after running some tests, provides Scott access to a Web interface with the report.

(A.5) Correct Drug Dosage. Scott needs to take a blood thinning drug like warfarin. His doctor, in order to better assess the right dosage for him, requests that Scott takes a genetic test. After collecting a DNA sample (e.g., saliva), the clinic runs some tests and, based on the results, the doctor prescribes the exact warfarin dosage for Scott.

(A.6) Correct Cancer Treatment. Scott is diagnosed with cancer. His doctor, prior to propose a treatment plan, requests that Scott takes a genetic test to assess whether or not he carries a certain DNA mutation. After collecting a DNA sample (e.g., saliva), the clinic runs some tests and, based on the results, the doctor suggests what the best treatment for Scott is.

After showing the above test scenarios, we presented a recap slide summarizing them. We then asked interviewees to compare those scenarios; specifically, we raised questions like "If you were in Scott's shoes, would you do all of these tests? Which ones would you not?" as well as more specific ones like "If you were Scott, which tests would you feel more inclined to do? Which tests more reluctant to?" Finally, we asked participants to actually rank the six tests from the one they felt most inclined to, to the one they felt most reluctant.

4.2.2 Experiment B: Attitude toward WGS

First, we presented to the participants one slide describing (with both text and pictures) Whole Genome Sequencing (WGS), i.e., the process of digitizing the complete DNA sequence of a human genome. We told participants that once a whole human genome is sequenced, all genetic tests, including those presented in Experiment A., could be performed on the sequenced data, using computer techniques. We also told them that computer techniques could be faster and cheaper than collecting a sample (and using expensive lab equipment) each time one needs a genetic test.

Afterwards, we presented (again, in random order) the following three scenarios.

(B.1) WGS with Healthcare Provider. Emma goes to see her primary care doctor, who tells her about the provider's experimental Whole Genome Sequencing program. He explains to her that, by having her genome sequenced, Emma may learn her genetic predisposition to diseases and conditions. He also tells her that the provider will keep her sequenced genome along with her medical information, so that they can use it to run genetic tests when needed for medical reasons. Also, the provider will offer a discount on the next healthcare bill.

(B.2) WGS with Personal Genomics Company. Emma

(B.2) WGS with Personal Genomics Company. Emma decides to have her genome sequenced by using a personal genomics company, such as, 23andMe.com. The company charges her \$100 to sequence her genome, give her a report about predisposition to diseases and conditions, and tell her about her genetic ancestry. Also, the company offers to store the data for her: if she wants to authorize her doctor to run some tests, she can grant him permission to contact the company.

(B.3) Data-only WGS (DVD). Emma decides to have her genome sequenced by using a sequencing laboratory, which charges her \$100 to sequence her genome and send her a DVD with the data.

After being presented with the above scenarios, participants were shown a recap slide. We then invited them to compare these scenarios; specifically, we asked "If you were Emma, would you participate in any of the three programs? and "Which program(s) would you feel more inclined to participate in? Which one(s) less inclined? Finally, we asked participants to rank the three scenarios from the one they felt most inclined to, to the one they felt most reluctant to.

4.2.3 Experiment C: Perception of privacy/ethics issues with WGS

In this experiment, we presented (in random order) the following four hypothetical cases.

(C.1) Labor Discrimination. Emma is interviewing for a job and her potential employer requests to run a drug

test and to access her genome. The employer finds out that Emma has predisposition to cancer and decides not to hire her.

(C.2) Health Insurance Discrimination. Emma wants to join a health insurance plan. The provider requests access to her medical record as well as her genome, and finds out that she has predisposition to leukemia. As a result, Emma needs to pay a higher premium.

(C.3) Sequenced Genome Stolen by Hacker. A hacker steals the file with Emma's sequenced genome and finds out her ethnicity/ancestry and that she has genetic predisposition to Huntington's disease.

(C.4) Sibling Donating Genome to Science. Emma's brother, Jack, decides to donate his genome to science (for medical research purposes). Since Emma's and Jack's genomes are 99.9% identical, Jack is actually "donating" Emma's genome as well but has not asked for her permission.

After being presented with the above scenarios, participants were shown a recap slide. We then asked to compare them; specifically, we asked: "If you were Emma, what incident(s) would give you the most discomfort? Which one(s) the least? Finally, we asked participants to rank the four scenarios from the one giving them the most discomfort, to the least.

4.2.4 Experiment D: Response to information loss

In the last experiment, participants were asked to *rank the following four incidents* (presented in random order) from the one they found most frightening to the least.

- (D.1) Identity. A hacker steals your financial information and your social security number, i.e., so-called "identity theft."
- (D.2) Medical records. A hacker hacks into your clinic's databases and steals all your medical records.
- (D.3) Emails and Pictures. A hacker hacks into your computer and steals your personal emails and pictures.
- (D.4) Sequenced Genome. A hacker steals the file containing your sequenced genome.

5 Study Results

We now present the results of our study, via a quantitative and qualitative analysis.

5.1 The issue of trust

During Experiment A, we asked participants to rank six genetic tests from the one they felt most inclined to, to the least. We report the average rankings, along with standard deviation, in Table 3a. (Rankings are on a 1-6 scale, with 6 being the case participants felt most inclined to, 1 the least.)

(A.6), i.e., correct cancer treatment, emerged as the test to which participants felt most inclined, with average ranking 5.81 (out of 6). 13/16 participants ranked (A.6) as the top one, and all of them among the top two. Next follow (A.5), i.e., correct drug dosage, and (A.2), i.e., genetic compatibility, with, respectively, 15/16 and 13/16 of participants ranking it among the top three.

At the other extreme, (A.3), ancestry testing, emerged as the test scenario most of participants (10/16) felt the least inclined to, with an overwhelming majority (12/16) ranking it among the bottom two. However, only 2 participants mentioned that they would not want to know their ancestry, while 8 reported that they would not mind discovering it but found medical tests much more relevant. Average ranking for (A.3) was 1.75, with a relatively high standard deviation of 1.09.

(A.1), i.e., disease predisposition (doctor), and (A.4), i.e., disease predisposition (company), were ranked relatively similar, mostly in the middle of the ranking scale. The former obtained a slightly higher average, i.e., 2.63 vs 2.13, although their difference was not statistically significant.

Participants exhibited a preference toward tests they considered immediately beneficial for their health (or that of their kids), such as, (A.6), (A.5), and (A.2). In fact, the rankings for (A.2), the test with lowest average in this category, and those for (A.1), the test with highest average outside this category, are statistically significant, as per Mann-Whitney U Test (U = 210.5, $n_1 = n_2 = 16$, P < 0.01, two-tailed).

Finally, it is interesting to observe the difference between (A.1) and (A.4): recall that, in both cases, the patient discovers the genetic predisposition to certain diseases. There were 9/16 participants ranking (A.1) higher than (A.4), and 5 out of 9 justified this choice due to a lower trust in a commercial company. For instance, P3 mentioned that she "would never trust a website with my genome." The other 4 participants instead mentioned that they would prefer a doctor to explain the test results, as the effects of genetic disease predisposition were not completely clear to them. On the other hand, 7/16 participants ranked (A.4) higher than (A.1): 2 of them justified this as they do not like to go to the doctor; 2 of them preferred a broader analysis of all predispositions; and, the remaining 3 did not want their healthcare provider to know about their predisposition, owing to fears of coverage denial or higher premiums.

5.2 The Issue of Control

In Experiment B, we aimed to understand and analyze participants' preference among three different options for Whole Genome Sequencing (WGS) programs. To this end, we asked participants to rank these options

Genetic Tests: More to less inclined	Avg	Stdev
(A.6) Correct Cancer Treatment	5.81	0.39
(A.5) Correct Drug Dosage	4.63	0.70
(A.2) Genetic Compatibility	4.06	1.25
(A.1) Disease Predisp. (Doctor)	2.63	0.99
(A.4) Disease Predisp. (Company)	2.13	0.70
(A.3) Ancestry Testing	1.75	1.09

(a) Ranking average and standard deviation for Exp A.

Incidents: More to less discomfort		Stdev
(C.1) Labor Discrimination	3.31	0.58
(C.2) Health Insurance Discrimination	3.00	0.94
(C.3) Sequenced Genome Hacked		0.93
(C.4) Sibling Donating Genome to Science	1.13	0.33

(c) Ranking average and standard deviation for Exp C.

WGS Programs: More to less inclined	Avg	Stdev
(B.3) Data-only (DVD)	2.68	0.58
(B.1) Healthcare Provider	2.00	0.71
(B.2) Personal Genomics Company	1.31	0.46

(b) Ranking average and standard deviation for Exp B.

Information loss: More to less frightened		Stdev
(D.1) Identity Theft	3.50	0.63
(D.3) Emails and Pictures	2.63	1.61
(D.4) Sequenced Genome	2.00	0.63
(D.2) Medical Records	1.88	0.48

(d) Ranking average and standard deviation for Exp D.

Table 3: Summary of Experiments.

from the one they felt most incline to, to the least. The average rankings, along with standard deviation, are reported in Table 3b. (Rankings are on a 1-3 scale, with 3 indicating the most favorite option, 1 the least favorite.)

The favorite option for a hypothetical WGS program was (B.3), i.e., data-only WGS (DVD), with more than two thirds of the participants (12/16) ranking it at very the top (average ranking 2.68 out of 3). Whereas, half of the participants (8/16) ranked option (B.1), WGS with healthcare provider, as their second favorite. Clearly, option (B.2), WGS with personal genomics company, seems to be the least preferred (1.31 average ranking), with two thirds of the participants (11/16) ranking it at the bottom, and 16/16 ranking it among the bottom two. In fact, the difference between the rankings of (B.2) and those of (B.1) is significant as per Mann-Whitney U Test $(U = 194, n_1 = n_2 = 16, P < 0.05, two-tailed)$.

We noticed that several participants, 12/16, mentioned that they wanted to feel in control of their genomic data. In particular, "control" was often used to justify the choice of ranking (B.3) as the preferred WGS option. Recall that 12/16 participants expressed preference toward (B.3), i.e., obtaining their sequenced genome on a DVD via a testing facility that would not retain data. Among these, 7 participants (6 male, 1 female) mentioned control as their main motivation for doing so, whereas, 5 users (all female) gave other reasons.³

P10 said "I would feel in control of my data,", while he would not trust it with the healthcare provider, as "they could hold it against me." And (B.2) would be "even worse as the company would not be subject to the same standards as a healthcare provider. Similarly, P14 reported she "would like to own and control my genome, or at least let my family do" and ranked (B.1) at the bottom, mentioning a complete lack of control in giving the information to a healthcare provider. Also, P12, P15, and P16 raised control as the main motivation to prefer (B.3);

nevertheless, P12 reported that he "wouldn't mind (B.1) if they can guarantee the same level of control," while both P15 and P16 mentioned that it would be necessary to trust the sequencing facility not to retain the raw data.

Next, we noticed that 7/16 participants responded negatively to the idea of receiving a discount on their next health bill in exchange for letting their provider sequence their genome and give a list of disease predispositions. P6 reported that "the discount looks fishy [...] are they going to make a deal with my genome?" P9 said "I don't care if I get a discount, I would prefer that they promise not to deny me coverage." On the other hand, P5, who ranked (B.3) higher than (B.1), pointed out that she would consider changing her mind if the discount was significant ("higher than \$1,000.")

Additional noteworthy remarks include P4 and P8 worrying of losing the DVD with the sequenced genome and P16's fear of being served personalized ads by a personal genomics company performing the sequencing.

5.3 The Issue of Discrimination

Experiment C aimed to assess perception of potential privacy/ethical issues associated with genomic tests and availability of whole genomes. Participants were asked to compare four different incidents and rank them from the one giving them the most discomfort, to the least.

The average rankings, along with standard deviation, are reflected in Table 3c. (Rankings are on a 1-4 scale, with 4 indicating the most frightening case, and 1 the least frightening.) *Note: unlike Experiment A and Experiment B, a higher ranking in Experiment C corresponds to a negative feeling.*

(C.1), i.e., labor discrimination, and (C.2), i.e., health insurance discrimination, represented the incidents giving most discomfort to the participants, with 12/16 participants ranking either one as the top. More specifically, almost one third of the participants (10/16) ranked (C.1) and (C.2) as the two incidents giving them most discomfort, owing to related discrimination issues. Their av-

³This also suggests a correlation between gender and preferring (B.3) because of increased control, with $\chi^2(1, N=32)=8.57 \ p<0.01$.

erage rankings were both above 3.00 (out of 4). (C.1) actually seems to be the most discomforting scenario as 15/16 participants placed it in the top two, compared to 11/16 for (C.2).

Then, 4/16 participants felt that (C.3), i.e., sequenced genome hacked, was the most discomforting scenario. 2 of these 4 users actually reported that (C.3) would imply (C.1) and (C.2), as a hacker could publish the genomic information or sell it to employers and healthcare providers. Whereas, the other 2 participants felt that they should be protected by the law as for (C.1) and (C.2).

(C.4), i.e., sibling donating genome to science, represented the case yielding the least discomfort, with 14/16 participants ranking it at the bottom, and 16/16 among the bottom two. The difference between rankings of (C.4) and those of (C.3), the second least discomforting case, was statistically significant, as per the Mann-Whitney U Test (U = 238.0, $n_1 = n_2 = 16$, P < 0.001, two-tailed).

Concerns related to discrimination were raised by several participants when motivating the rankings in Experiment C, but also, indirectly, when discussing their concerns with respect to Whole Genome Sequencing.

10/16 participants ranked (C.1) higher than (C.2): when asked why, 5 out of these 10 participants reported that somehow (C.2) was not too surprising. P5, P6, and P16 actually said that healthcare cost discrimination already happens today, so (C.2) would be somewhat expected. P16 also mentioned that (C.2) "is understandable, they will be the ones to pay, and they already take into account predisposition and pre-existing conditions."

Discomfort from (C.1) was often paired with an unfairness feeling. P7 pointed out that predisposition "does not necessarily mean that I will get the disease," and P1 that predisposition "doesn't mean that I won't be able to perform my job."

Finally, (C.4) was the least frightening case for 14/16 participants: 9 of these said they were not concerned since the genome is donated to science, for a good cause, and 5 trusted the research lab having access to their genome, since, as pointed out by P13, "labs are subject to ethical reviews and will not share data with anyone."

5.4 The Issue of Damage from Information Loss

The last experiment aimed to compare participants' response to incidents involving information loss. We asked them to rank four hypothetical cases from the one they considered most frightening to the one they considered least. The average rankings, along with standard deviation, are reported in Table 3d. Rankings are on a 1-4 scale, with 4 indicating the most frightening case, and 1 the least frightening.) Again, unlike Experiment A

and Experiment B, and similar to Experiment C, a higher ranking in Experiment D corresponds to a negative feeling.

(D.1) represented the most frightening case for most participants, with an average ranking of 3.50 (out of 4). Indeed, 10/16 participants ranked it as the most frightening scenario and 15/16 among the top two. Then follows (D.3), with 6/10 participants ranking it at the top. Observe that the average ranking is relatively low (2.63) with a high standard deviation (1.61); almost half of the participants (7/16) ranked it among the bottom two cases, and 5/16 at the very bottom.

(D.4) and (D.2) were ranked similar, with average ranking, resp., 2.00 and 1.88, and no one labeling them as the most frightening. We observed no statistically significant difference between the two, suggesting that participants are almost equally frightened with a hacker stealing their medical records or their sequenced genome. But, we did observe a statistically significant difference between (D.1) and (D.4), suggesting that participants are not as frightened by loss of genomic information as they are of identity theft (U = 230, $n_1 = n_2 = 16$, P < 0.001, two-tailed).

We observed that several participants often used the degree of damage produced by each incident involving information loss to identify the most frightening cases. Experiment D also exhibited some interesting correlations with participants' demographics. We observed that most users with incomes lower than 50K were most frightened by (D.3), i.e., their personal emails and pictures being stolen (5/6), as opposed to very few users (1/10) with higher incomes ($\chi^2(1, N = 32) = 8.60 \ p < 0.01$). Whereas, users with incomes higher than 50K were most frightened by their identity being stolen (D.1), i.e., 9/10 vs 1/6, respectively ($\chi^2(1, N = 32) = 8.60 \ p < 0.01$).

Next, we noticed that no privacy fundamentalist was most frightened by loss of personal emails and pictures (0/5), as opposed to a slight majority of pragmatists/unconcerned (6/11). Whereas, privacy fundamentalists were most frightened by identity theft (5/5) as opposed to 5/11 for non-fundamentalists. In both cases, it holds $\chi^2(1,N=32)=4.36$ p<0.05, thus, there might be a statistically significant correlation between the Westin privacy index and being most frightened by either identity theft or loss of emails/pictures.

Reasons for such correlations can be explained by noticing that participants used the degree of damage as the discriminant among information loss cases. Ostensibly, high-income users have more to lose (money- and financial-wise) from identity theft – e.g., P11 mentioned "It would cost me too much time and money." Also, privacy fundamentalists might not be afraid of emails and pictures being stolen as they feel they take the appropri-

ate precautions – e.g., P2 reported "I always encrypt my sensitive emails and do not keep pictures on my laptop."

5.5 Take Away

In summary:

- Perception of genetic tests seemed to depend on the related perceived medical benefit. Participants were mostly inclined to genetic tests that can help fight diseases, but less to tests that can help prevent them. Also, they were neutral w.r.t. discovering their ancestry.
- On the account of trust, participants preferred that doctors administered medical genetic tests, rather than specialized personal genomics companies.
- 3. Participants raised the issue of control and preferred to retain and own data with their sequenced genome, to minimize their fear of potential discrimination.
- 4. Labor and healthcare discrimination were the top concerns among interviewees, with an increase unfairness feeling associated with the former, and a lack of confidence in the protection granted by the law. Fear of discrimination was predominant, compared to privacy threats, which were not fully understood by participants.
- 5. Participants were more frightened by having their financial identity and/or personal data stolen (with a bias toward the former for high-income, privacy fundamentalist users) than medical and genomic information. However, the perception of genomic information loss varied significantly among different participants and suggested that participants were more scared of their insurance provider or their employer using genomic information against them than of a hacker having access to it.

6 Conclusion

This paper presented the results of a series of semistructured interviews involving 16 participants, that aimed to assess the perception of genetic tests, the attitude toward different Whole Genome Sequencing (WGS) programs, as well as the perception of associated privacy and ethical issues. The results of our interviews were analyzed both quantitatively and qualitatively, suggesting that the issues of control, trust, and discrimination are crucial aspects that the community should take into account, not only from a policy standpoint, but also for user-centered designs of WGS applications.

Our exploratory research highlights the need for more ethnographic studies in the field and the importance of informing the public with respect to privacy threats associated with genomic information disclosure and legal rights addressing discrimination issues. Naturally, our work does not end here. As part of future work, we plan to run a larger user study further clarifying some of the issues discussed in this paper. We are also working on a gamification strategy to raise awareness of privacy, ethical, and legal issues of Whole Genome Sequencing.

Acknowledgments. We would like to thank participants who volunteered for the study. We are grateful to Honglu Du for his invaluable feedback, and to Darya Mohtashemi, Greg Norcie, and Julien Freudiger for their helpful comments.

References

- [1] A. Abbott. Special section on human genetics: With your genes? Take one of these, three times a day. *Nature*, 425(6960), 2003.
- [2] L. B. Andrews. Future perfect: confronting decisions about genetics. Columbia University Press, 2001.
- [3] D. Benjamin et al. The genetic architecture of economic and political preferences. *Proceedings of the National Academy* of Sciences, 109(21), 2012.
- [4] J. L. Bottorff et al. WomenÕs interest in genetic testing for breast cancer risk the influence of sociodemographics and knowledge. *Cancer Epidemiology Biomarkers & Prevention*, 11(1), 2002.
- [5] K. B. Brothers, D. R. Morrison, and E. W. Clayton. Two large-scale surveys on community attitudes toward an opt-out biobank. *American Journal of Medical Genetics*, 155(12), 2011
- [6] M. Bruno et al. Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population. *Annals of Oncology*, 15, 2004.
- [7] A. Burke. Foundation Medicine: Personalizing Cancer Drugs. MIT Technology Review, 2012. http://techre. vu/Xic52g.
- [8] T. Canli. The emergence of genomic psychology. *Nature*, 8, 2007.
- [9] S. Cichon, M. Nöthen, M. Rietschel, and P. Propping. Pharmacogenetics of schizophrenia. *American Journal of Medical Genetics*, 97(1), 2001.
- [10] F. Collins and V. McKusick. Implications of the Human Genome Project for medical science. *Jama*, 285(5), 2001.
- [11] K. Darcè. Illumina drops sequencing price to \$4,000. UT San Diego, 2011. http://preview.tinyurl.com/ illumina-drops-prices.
- [12] R. Drmanac et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science, 327(5961), 2010.
- [13] J. Fowler, J. Settle, and N. Christakis. Correlated genotypes in friendship networks. *Proceedings of the National Academy* of Sciences, 108(5), 2011.
- [14] U. Francke et al. Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing. *PeerJ*, 1, 2013.
- [15] M. Fumagalli et al. Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions. *Experimental Medicine*, 206(6), 2009.

- [16] L. N. Geller et al. Individual, family, and societal dimensions of genetic discrimination: a case study analysis. *Science and Engineering Ethics*, 2(1), 1996.
- [17] Genetics and public policy center. U.S. Public Opinion on Uses of Genetic Information and Genetic Discrimination. http://preview.tinyurl.com/gina-public-opinion, 2007.
- [18] G. Ginsburg and H. Willard. Genomic and personalized medicine: foundations and applications. *Translational Re*search, 154(6), 2009.
- [19] R. C. Green et al. Disclosure of APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine, 361(3), 2009.
- [20] A. E. Guttmacher, F. S. Collins, and E. W. Clayton. Ethical, legal, and social implications of genomic medicine. *New England Journal of Medicine*, 349(6), 2003.
- [21] M. Gymrek, A. L. McGuire, D. Golan, E. Halperin, and Y. Erlich. Identifying personal genomes by surname inference. *Science*, 339(6117), 2013.
- [22] M. A. Hall and S. S. Rich. Patients' fear of genetic discrimination by health insurers: the impact of legal protections. *Genetics in Medicine*, 2(4), 2000.
- [23] K. Hallam. Oxford Nanopore To Sell Tiny DNA Sequencer. http://bloom.bg/Aogf12, 2012.
- [24] J. G. Hamilton, M. Lobel, and A. Moyer. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. *Health psychology*, 28(4), 2009
- [25] N. Homer et al. Resolving individuals contributing trace amounts of DNA to highly complex mixtures using highdensity SNP genotyping microarrays. *PLoS Genetics*, 4(8), 2008.
- [26] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. *Nature*, 409, 2001.
- [27] D. J. Kaufman, J. Murphy-Bollinger, J. Scott, and K. L. Hudson. Public opinion about the importance of privacy in biobank research. *American Journal of Human Genetics*, 85(5), 2009.
- [28] P. Kumaraguru and L. F. Cranor. Privacy indexes: A survey of Westin's studies. http://reports-archive.adm. cs.cmu.edu/anon/isri2005/CMU-ISRI-05-138.pdf, 2005.
- [29] E. V. Lapham, C. Kozma, and J. O. Weiss. Genetic discrimination: perspectives of consumers. *Science*, 274(5287), 1996.
- [30] S. Levy et al. The diploid genome sequence of an individual human. *PLoS biology*, 5(10), 2007.
- [31] B. Malin. An evaluation of the current state of genomic data privacy protection technology and a roadmap for the future. *Journal of the American Medical Informatics Association*, 12(1), 2005.
- [32] B. Malin. Re-identification of familial database records. In AMIA, 2006.
- [33] B. Malin and L. Sweeney. Re-identification of DNA through an automated linkage process. In AMIA, 2001.
- [34] B. Malin and L. Sweeney. How (not) to protect genomic data privacy in a distributed network: using trail re-identification to evaluate and design anonymity protection systems. *Journal* of *Biomedical Informatics*, 37(3), 2004.

- [35] V. McKusick and S. Antonarakis. Mendelian inheritance in man: a catalog of human genes and genetic disorders. John Hopkins University Press, 1994.
- [36] S. Moore. Moore's Law Leads to \$1000 Genome Device. IEEE Spectrum, January 2012.
- [37] National Center for Biotechnology Information (US). Single Nucleotide Polymorphism Database. http://www.ncbi.nlm.nih.gov/projects/SNP/.
- [38] J. Oldenburg, M. Watzka, S. Rost, and C. Müller. VKORC1: Molecular target of coumarins. *Journal of Thrombosis and Haemostasis*, 5(s1), 2007.
- [39] A. Prat and J. Baselga. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of her2. *Nature Clinical Practice Oncol*ogy, 5(9), 2008.
- [40] Presidential Commission for the Study of Bioethical Issues. Privacy and Progress in Whole Genome Sequencing. http://www.bioethics.gov/cms/sites/default/files/PrivacyProgress508.pdf, 2012.
- [41] M. A. Quail, I. Kozarewa, F. Smith, A. Scally, P. J. Stephens, R. Durbin, H. Swerdlow, and D. J. Turner. A large genome center's improvements to the Illumina sequencing system. *Nature methods*, 5(12), 2008.
- [42] M. Ruiz-Canela, J. I. Valle-Mansilla, and D. P. Sulmasy. What research participants want to know about genetic research results: The impact of Ogenetic exceptionalismO. Journal of Empirical Research on Human Research Ethics, 6(3), 2011.
- [43] H. Shen. California considers DNA privacy law. Nature, 2012. http://preview.tinyurl.com/ california-dna-law.
- [44] K. R. Smith and R. T. Croyle. Attitudes toward genetic testing for colon cancer risk. American Journal of Public Health, 85(10), 1995.
- [45] P. Stenson et al. The human gene mutation database: 2008 update. *Genome Medicine*, 1(1), 2009.
- [46] S. B. Trinidad et al. Genomic research and wide data sharing: views of prospective participants. *Genetics in Medicine*, 12(8), 2010.
- [47] M. Wadman. Genetics bill cruises through senate. *Nature*, 453, 2008.
- [48] R. Wang et al. Learning your identity and disease from research papers: information leaks in Genome Wide Association Study. In CCS, 2009.
- [49] D. Wheeler et al. The complete genome of an individual by massively parallel DNA sequencing. *Nature*, 452(7189), 2008
- [50] S. Williams. The genetic town hall: Public opinion about research on genes, environment, and health. http:// preview.tinyurl.com/genetic-town-hall, 2009.
- [51] S. Wood. RAPID GENE: Point-of-care genetic test singles out clopidogrel nonresponders. http://www.theheart. org/article/1379471.do, 2012.